Zhou Jiang | VP of Early Commercial and Corporate Strategy
Edgewise Therapeutics
Zhou is an industry veteran with over a decade of experience leading New Product Planning and Commercialization in Nephrology, Hematology, Metabolic, Respiratory, Neuromuscular rare diseases. Currently serving as the Vice President of Early Commercial and Corporate Strategy at Edgewise Therapeutics, Zhou is a strategic thinker with a proven track record of driving business growth and market expansion in the rare disease and orphan drug space.
Appearances:
Day 1- World Orphan Drug Congress USA 2025 @ 11:45
Fireside chat: Challenges and approaches for patient identification in Rare Diseases
Patient identification in rare diseases is critical to drug development, commercialization and optimizing patient care and outcomes. Patient identification often hits roadblocks after exhausting the initial wave of diagnosed and engaged individuals, leaving many potential patients underserved. To truly maximize the impact of innovative treatments and the power of integrated care, it’s critical to understand how patients navigate the complexities of the healthcare system and identify gaps in care. In this session, we’ll explore the unique challenges of patient identification and management in rare diseases, while sharing practical, actionable strategies to drive better outcomes. Join us for an engaging and interactive discussion!
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events